Compare BCHT & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCHT | JSPR |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.9M | 26.3M |
| IPO Year | 2016 | 2019 |
| Metric | BCHT | JSPR |
|---|---|---|
| Price | $0.97 | $11.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $249.83 |
| AVG Volume (30 Days) | 57.5K | ★ 257.9K |
| Earning Date | 11-12-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.22 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,626,366.00 | N/A |
| Revenue This Year | $4.39 | N/A |
| Revenue Next Year | $45.11 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.26 | N/A |
| 52 Week Low | $0.97 | $0.32 |
| 52 Week High | $2.59 | $17.03 |
| Indicator | BCHT | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 33.08 | 62.78 |
| Support Level | N/A | $0.64 |
| Resistance Level | $1.51 | $17.03 |
| Average True Range (ATR) | 0.13 | 1.49 |
| MACD | -0.00 | 0.21 |
| Stochastic Oscillator | 0.03 | 61.42 |
Birchtech Corp is a provider of specialty activated carbon technologies, delivering solutions for air and water purification. It provides patented and proprietary Sorbent Enhancement Additive (SEA) technologies for mercury emissions capture to the coal-fired utility sector, and is developing water purification technologies with a specialization on forever chemicals such as PFAS and PFOS. Geographically, the company derives all of its revenue from the United States.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.